Manager TitleAgeSince
Corporate Secretary 60 07/08/2019
Director TitleAgeSince
Director/Board Member 60 06/06/2019
Director/Board Member 49 20/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-1.79%-2.27%+43.23%+99.78% 67.98B
-2.60%-0.71%+34.08%+81.43% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
-1.10%-0.33%+24.88%+16.32% 25.74B
-1.04%+1.56%+23.92%-17.97% 20.09B
-2.96%-15.21%+216.20%+375.70% 17.16B
+0.08%-1.33%-6.82%+549.80% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average -0.89%+0.26%+41.18%+181.65% 31.01B
Weighted average by Cap. -1.36%+0.18%+36.32%+140.69%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!